BIIB icon

Biogen
BIIB

Overview Fund Trends Analyst Outlook Journalist POV
143.66 USD
--1.65
1.14%
At close Updated Oct 15, 4:00 PM EDT
Pre-market
After hours
143.75
+0.09
0.06%
1 day
-1.14%
5 days
-5.09%
1 month
0.24%
3 months
12.67%
6 months
22.81%
Year to date
-4.23%
1 year
-25%
5 years
-48.81%
10 years
-46.48%
 

About: Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

Employees: 7,605

Healthcare Drug Manufacturers - General
0
Funds holding %
of 7,493 funds
Explore Fund Trends
0
Analysts bullish %
of 6 analysts
See Analyst Outlook
0
Positive news %
of 19 articles
Check Journalist POV
Price charts implemented using Lightweight Charts™